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As of June 2016 there are 28 medical schools [1] in 
both private and public sectors in Malaysia offering 
more than twice as many programs [2] with yearly 
graduates of about 4500 including those that graduated 
from overseas. This magnitude is beyond the usual 
capacity of Ministry of Health (MOH) that is entrusted 
to accord preregistration training posts to the graduates 
as the whole process of allocation to available places in 
public hospitals nationwide is painfully slow. It is 
already a tragedy having to wait 6 months on average 
for a placement but words that a delay for up to a year 
can occur is totally unacceptable when the actual 
training places available at grade DU41 preregistration 
house officers is said to be more than the graduate 
number [3]. Delay can be detrimental to the training 
itself because waiting is a waste of talent and potential, 
a disincentive to a young aspirant, tacitly is a testimony 
of system failure and deprives the public of highly 
trained graduates to serve in our healthcare system that 
ironically suffers from chronic and ever growing wait 
but yet we have excess medical graduates. Some of 
them have taken a simple and quick route out of the 
mess by migrating to our neighbours near and far, not 
entirely their faults, but their thresholds to despair seem 
very low indeed. The need for a speedy and right 
solution to the delay is long overdue and this is nothing 
more than what the public and the young doctors 
deserve. 
  How did we get to this? Not unexpectedly but 
the magnitude stemmed from the unusually large 
number of Sijil Pelajaran Malaysia (SPM; Malaysia 
Certificate of Education) leavers that opted to study 
medicine, in part made easy by the many medical 
schools in the country and those that have been 
accredited abroad. This was augmented by the constant 
reminder of the need for more doctors, parental or hype 
pressure perhaps for whatever reasons, and also the ease 
with which scholarships were available to study 
medicine. The principle driver for the whole mess was 
money initiated by those who wish to make profits 
under these “fortunate” circumstances [4]. The resulting 
deluge of medical graduates clogged the system up and 
unfortunately created many of the unnecessary 
challenges that we face today. Paradoxically despite 
this excess our doctor population ratio is still lower than 
the Organization for Economic Cooperation and 
Development (OECD) average and our more 
prosperous neighbour in the south. These veiled and 
unscrupulous drivers are addressing the gap in ratio 
with such a speed that it strains the system to almost 
breaking point and had somewhat ruffled both Ministry 
of Higher Education (MOHE) and MOH. 
  The doctor number that we need should ideally 
be planned or rather managed at this point and this can 
only be done by addressing all the factors that had led 
us to this. For a start we should look at the basic 
question of what the country needs in the future (2020 
and beyond) and then work backwards. This sounds 
simple enough but in practice this is where the 
challenge lies. Two ministries MOH and MOHE are 
both looking at the issue albeit with different focus but 
inevitably with some overlapping jurisdiction. The 
MOH concerns with the nation’s health issues and 
MOHE deals with medical education and consequently 
doctor number, although seemingly separate but in 
actual fact they will converge. Whatever the number of 
medical students approved at Malaysian Qualifications 
Agency (MQA) / Malaysian Medical Council (MMC) 
or sponsored by Jabatan Perkhidmatan Awan (JPA; 
Public Services Department) /MOHE the final tally in 
five years will be the medical graduates that will have 
to be allocated to training places. Too many medical 
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graduates too soon appear to be the main problem and 
therefore it is high time that we try to regulate the 
number that goes into training. Immediate actions are 
required too to restore public confidence in the light of 
unsympathetic media comments. This includes policies 
that require hard choices such as derecognizing some 
foreign medical schools in the archaic list of schedule 2 
and introducing the right to practice examination for 
those who have graduated from abroad. Both can 
regulate number and consequently emphasize quality. 
  The next challenge is the specialist number 
now that doctor number at lower grades will address the 
gap in ratio in time. Although a lot has improved but by 
most estimates the number of specialists must double to 
take up the challenges of a developed nation status and 
we need to add to this the question of disparity (uneven 
number by specialty) and geographical mal-distribution, 
unfortunately the issues remain despite numerous 
incentives introduced by MOH over the years. An 
easier question of churning up specialist number can be 
addressed rather immediately because we have a robust, 
economical, and internationally respected system within 
our midst that is the Master in Medicine (MMED). But 
when the issue of increasing the specialist number is 
debated, the discourse mystically takes a pathetic 
course to the times when postgraduate medicine began 
in the country in the 60s, a return to our colonial 
ancestry for training opportunities and supervision. 
When postgraduate medicine first started we indeed 
relied heavily on the hospitals in the United Kingdom 
(UK) and their college exams but these are things of the 
past. Except for stated and specific niche areas for 
training and education, or occasional exception, by and 
large we have existed and trained our specialist 
independently from the system in the UK for more than 
three decades. For the record, to date more than 8000 
specialists have graduated from MMED system and for 
a rapidly growing Malaysia this number is huge. 
Especially so for the surgical based specialties that are 
the most challenging to train and in all domains the 
surgeons have been at par with the very best in the 
world. In fact from our own survey, MMED trained 
specialists are the backbone of doctors that service the 
public hospitals and clinics in Malaysia. 
 
  Despite this apparent regression, the 
universities that offer MMED are in the process of 
institutionalizing the training pathway and system to 
maintain the quality and improve the process further. 
Steps are taken to formalize the training pathway via 
MQA and MOHE to reinforce public perception of the 
system and in preparation for soon to be implemented 
trade and economic liberalization in ASEAN. For 
practical purposes the MMED system essentially has 
two types; one that is based on the presence of the 
faculty’s own teaching hospital and the other on the 
absence of one and thus reliance on the state hospital as 
the faculty’s affiliated teaching hospital. Both models 
have achieved success and maintained the quality and 
competency required by a robust comprehensive 
assessment system that includes standardized 
examinations attended by a wide selection of examiners 
in the country and abroad. In the next 5 years or so, the 
training environment to some extent the MMED will 
undergo a significant change with the completion of 
another 7 teaching hospitals and the incorporation of a 
consortium of university teaching hospitals. With an 
estimated number of nearly 10000 tertiary care beds at 
peak activity this will provide an excellent opportunity 
to train more specialists and partake in subspecialty 
training. This includes research and teaching activities 
that will enhance the return on investment to the public. 
  Based on the cumulative years of experience 
and a much more organized MQA the future of medical 
education for both undergraduate and postgraduate 
looks very promising indeed but the main lingering 
issues in both must be addressed. For undergraduate 
medicine the need to maintain a robust and stringent 
control on quality is paramount and data shows that the 
emphasis of this is mainly on graduates from some 
foreign medical schools because the local ones are 
subject to very stringent accreditation exercise and 
compliance audit, therefore quality is assured. Another 
strategy to achieve this is the introduction of fitness to 
practice examination for foreign medical school 
graduates. Both will help control number. The main 
issue that is affecting postgraduate education is the need 
to institutionalize the MMED for the future and the 
creation of teaching hospitals consortium by working 
closely with MQA and MOHE. This will ensure the 
best deal for the public. The future is in our hands. 
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INTRODUCTION 
One of the most common inheritable cardiac disorders 
is hypertrophic cardiomyopathy (HCM) with an 
approximated prevalence of 1:500 in the general 
population [1]. Penetrance tends to remain incomplete 
as it increases with age. HCM is inherited as a 
mendelian autosomal dominant trait in approximately 
50 – 60 % of cases, which to date has more than 600 
mutations identified in sarcomeric genes [2, 3]. 
However, autosomal recessive, X-linked, and 
mitochondrial (matrilinear) patterns of inheritance can 
also occur [3]. Like some inherited cardiomyopathies 
HCM reveals marked phenotypic variability that occur 
even within the families.  
 HCM may be defined as segmental or diffuse 
left ventricular (LV) hypertrophy in a hyperdynamic 
and nondilated chamber but with absence of other 
cardiac or systemic diseases which are able to produce 
the degree of hypertrophy that is evident [3]. The 
major characteristics of HCM include fibrosis, 
myocyte disarray and arcane cardiac hypertrophy. The 
histopathologic hallmarks of HCM is myofibrillar  
 
disarray and myocyte with a haphazard or non-linear 
arrangement of myocytes on light microscopy [4]. 
Another histopathological finding is an abnormal 
dysplasia of the intramural coronary arterioles 
occuring due to increased pressure from adjacent 
hypertrohic myocytes.  
 Due to the genetic diversity together with 
modifier genes and environmental factors there is a 
wide range of penetrance and phenotypic expression, 
the most common pattern being the asymmetric 
involvement of the interventricular septum. In majority 
of cases HCM can be phenotypically expressed either 
in early adulthood or even adolescence. Although it 
has been seen that in certain phenotypes, age-related 
penetrance is becoming increasingly recognized 
whereby there can be delayed emergence of left 
ventricular hypertrophy (LVH) in midlife and beyond 
[5]. 
 Although there is a wide range of clinical 
manifestation for HCM, the most common features of 
the disease are systolic with or without diastolic 
dysfunction, left ventricular outflow tract obstruction 
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(LVOTO), supraventricular/ventricular arrhythmias 
and even sudden cardiac death (SCD).  
 The clinical and electrocardiography findings 
of HCM are diverse and nonspecific. This is where 
non-invasive imaging modalities such as cardiac 
magnetic resonance (CMR) can contribute in not only 
detecting HCM but also comprehend the 
pathophysiology. CMR has various roles in the 
evaluation of HCM, and these include: diagnosing the 
disease, characterization of its phenotype, assessing 
the cardiac function, determining whether or not there 
is dynamic obstruction and classifying the disease 
severity. It can also be used as a guide for suitable 
therapy, risk stratification and screening tool for the 
family. 
 The diagnosis of HCM traditionally relied on 
clinical manifestations and transthoracic 
echocardiography (TTE) in identifying unexplained 
LVH in a non-dilated LV cavity. Other supporting 
features on imaging include LVOTO and/or systolic 
anterior motion (SAM) of the mitral valve. Due to 
certain technical limitations and the highly variable 
nature of HCM phenotypic expression, TTE 
assessment is unable to confidently establish or refute 
a diagnosis of HCM. TTE can underestimate the 
degree of LVH which can delay proper treatment and 
prevent sudden cardiac death
 
[6]. 
 Not only can CMR distinguish HCM from 
other causes of LVH but it can reliably establish the 
diagnosis and hence help identify those at risk of SCD. 
Using steady-state free precession (SSFP) pulse 
sequence, CMR allows multiplanar imaging where the 
entire myocardium is covered. Hence allowing a better 
depiction in the distribution and array of LVH. These 
sequences also allow excellent contrast between the 
endocardium and blood pool. Using late gadolinium 
enhancement (LGE) images presence of myocardial 
fibrosis or scarring can provide further information on 
tissue characterization. Aside from that stress cardiac 
MRI can be used to evaluate the state of the 
myocardial blood flow.  
 In majority of HCM patients, septal 
hypertrophy can directly cause LVOTO, but LVOTO 
may also be seen in the presence of minimal septal 
thickening as the result of variant papillary muscle and 
subvalvular anatomy which highlights the importance 
of accurate anatomical assessment [7]. Patients with 
HCM have shown to have a higher incidence of 
anomalous papillary muscles including bifid and 
accessory papillary muscles, as well as antero-apical 
papillary muscle displacement. In 10 – 15 % of HCM 
patients, there is focal segmental LVH typically 
limited to the posterior septum, anterolateral free wall 
or even the apex, which are technically challenging 
areas for TTE, due to limitations of imaging windows 
[6]. 
 CMR has a useful role in surgery, in the pre-
operative planning for patients undergoing surgical 
myectomy where echocardiographic images have 
found to be suboptimal. It can assist patients with 
multiple levels of LV obstruction, such as those with 
mid-cavity and LVOTO and also in those with 
abnormalities of the right ventricular outflow tract 
(RVOT). Following surgery, CMR can identify the 
area of scarring and regression of the myocardium. In 
addition, it can calculate the sum of tissue necrosis 
caused by septal alcohol ablation. 
 In past few years MRI is now established as a 
useful adjunct to TTE owing to its unrestricted field of 
view, more accurate assessment of LV wall thickness, 
mass, volumes and function and its ability to provide 
non-invasive assessment of myocardial fibrosis. Due to 
the growing evidence-based practice most cardiac 
imaging centres now routinely perform CMR in all 
new patients with suspected HCM as endorsed by the 
American Society of Echocardiography 2011 
consensus guidelines [8]. 
 
Cardiac MRI Technique 
Standard HCM protocol with addition of flow sensitive 
sequences and stress perfusion imaging in selected 
cases can be used to help diagnose HCM.  
Steady State Free Precession (SSFP) 
Sequences  
Cine imaging with bright blood SSFP sequences 
produces high definition of the blood pool-
myocardium interface and forms the basis of 
morphological assessment. SSFP images in 
standardised 2-, 3- and 4-chamber planes also provide 
additional morphological assessment. Cine sequences 
imaged in the short axis plane which are acquired from 
the base to the apex allows identification and 
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measurement of hypertrophied regions, ejection 
fraction, LV volumes, and LV mass (with semi-
automated post processing software). LGE imaging 
provides non-invasive tissue characterization by 
identification of HCM associated interstitial and 
replacement fibrosis. 
 
Late Gadolinium Enhancement in HCM 
LGE has been recognised in many disease processes 
involving the myocardium including myocardial 
infarction, myocarditis and cardiomyopathy. The 
precise pathophysiology of LGE in HCM remains 
unclear. There are two hypothesis: some studies 
suggests that LGE may be due to a pathophysiologic 
cascade where repetitive bouts of microvascular 
ischemia occurs from replacement fibrosis due to 
myocyte cell death and repair as a result of structurally 
abnormal intramural coronary arteries. Another 
hypothesis proposes that the increased myocardial 
connective tissue deposition can be directly caused by 
the causative sarcomeric gene mutations [7]. 
 The most commonly seen LGE pattern in 
HCM is the patchy mid-wall-type enhancement which 
is characteristically most evident within the segments 
which are severely hypertrophied [9] (Figure 1). LGE 
usually involves the interventricular septum, 
particularly the right ventricular insertion points and 
anteroseptal mid to basal segments [7]. 
 
 
Figure 1 Extensive patchy diffuse mid wall hyperenhancement in the 
hypertrophied parts (arrow) involving non-coronary distribution. 
 
 Studies have shown that a higher frequency of 
ventricular extrasystoles, non-sustained and induced 
VTs are likely to develop in patients with LGE [10]. 
 
Phase Velocity Flow Mapping Sequences 
To calculate the peak velocity of blood flow through 
the LVOT, phase velocity flow mapping sequences 
can be employed. This is done in the cases where there 
is left ventricular outflow tract obstruction (LVOTO). 
The drawback is proper aligning of the imaging plane 
in order to attain the highest flow velocities which is 
not only inclined to error but is time-consuming as 
well. Accurate quantification of turbulent flow can be 
difficult because of signal loss and intravoxel 
dephasing due to phase offset errors. Hence for 
quantification of LVOTO Doppler echocardiography is 
the modality of choice. 
 
Disease Characterization 
 
HCM phenotypes 
Phenotypic heterogeneity causes great variability in 
the imaging appearances of HCM which can present 
significant diagnostic challenges when trying to 
establish the diagnosis [11]. HCM can involve any part 
of the left ventricle. The commonest HCM phenotype 
is asymmetric septal hypertrophy. The other variants 
of HCM include apical, symmetric or concentric, 
midventricular, noncontigous, masslike, reverse-curve 
and sigmoid HCMs. MRI is useful in these variants 
due to its complete unrestricted coverage of the LV, 
especially when disease is confined to just a few 
myocardial segments separated by regions of normal 
wall thickness. The diagnosis of HCM can be made 
when there is a LV wall thickness which is equal to or 
more than 15mm in the end-diastolic phase. In HCM 
cases involving a limited number of LV segments the 
LV mass will often be within the normal range.   
 Right ventricular hypertrophy has been seen in 
15 – 20 % of patients with HCM and most often 
affects the mid-to-apical portion of the right ventricle, 
often contiguous with LVH. There are sporadic case 
reports of HCM causing right ventricular outflow tract 
obstruction [12]. 
Asymmetric (Septal) HCM 
The most common form of HCM is the asymmetric 
HCM and accounts for approximately 60 – 70 % of 
cases [3]. The diagnosis for this form of the disease is 
made when: 1) the septal thickening is equal to or 
more than 15 mm or 2) when the ratio between the 
thickness of the septal wall and the inferior wall of the 
left mid-ventricular myocardial wall is more than 1.5 
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(Figure 2). In this HCM phenotype the hypertrophy is 
characteristically seen in the anteroseptal portion of the 
myocardium. 
 Clinically it is crucial to differentiate between 
the obstructive and nonobstructive HCM. This is done 
by determining whether there is a gradient between the 
LVOT and the aorta whereby the patient is both at rest 
 
Figure 2 Depiction of asymmetrical septal hypertrophy (arrowhead) SSFP 
in four chamber (Fig A) and short axis views (Fig B). 
and/or on exertion [3]. About 20 – 30 % of those with 
this form of the disease have systolic anterior motion 
(SAM) of the mitral valve leaflet and mid-systolic 
contact with the interventricular septum (Figure 3) 
[13]. Mitral regurgitation can be present occurring 
because of SAM and inadequate leaflet apposition. 
SAM is not only seen in HCM as it can also occur in 
patients following mitral valve repair or dysfunction, 
hypertensive hearts, diabetes mellitus, and acute 
myocardial infarction. SAM of the mitral leaflets can 
be clearly demonstrated on cine imaging sequences. 
 
 
 
Figure 3 Cine steady-state free precession 3-chamber view shows 
asymmetric septal hypertrophy (double arrowhead). The left ventricular 
outflow tract is narrow due to SAM of the anterior leaflet of the mitral valve 
(arrow). A jet (arrowhead) due to mitral regurgitation is seen. 
Apical HCM 
In apical hypertrophic cardiomyopathy the myocardial 
hypertrophy is predominantly in the LV apex [12]. The 
criteria for diagnosing this form of the disease is either 
an apical myocardial thickening greater than 15mm or a 
1.3 – 1.5 ratio of apical to basal LV myocardial 
thickness [14, 15]. On vertical long axis view at end-
diastole due to localized apical hypertrophy, the LV 
cavity can be seen at times to have a “spade-like” 
shape. MRI has proven clinical utility in its diagnosis 
and characterization as this HCM subtype can be 
overlooked on TTE due to acoustic window limitations. 
Symmetric HCM (Concentric HCM) 
The diagnositic criteria for symmetric or concentric 
HCM is a symmetric/concentric increase of the LV 
myocardium with markedly reduced cavity with no sign 
of a secondary cause. This type of HCM should be 
differentiated from causes of symmetric LV 
hypertrophy, like sarcoidosis, amyloidosis, Anderson-
Fabry disease, athletic remodeling and the adaptive 
pattern of myocardial hypertrophy secondary to 
hypertension or aortic stenosis. 
 
Midventricular HCM 
A rare form of asymmetric HCM is midventricular 
HCM which is characteriszed by hypertrophy which 
occurs in the mid third of the LV myocardium and the 
systolic apposition of the mid myocardial wall [12]. The 
detection of this variant is important as it is linked with 
myocardial necrosis, systemic embolism, ventricular 
arrhythmias and apical aneurysm. Apical aneurysm is 
believed to be a result of chronically increased systolic 
pressures occuring in the apex as a result of 
midventriuclar obstruction. 
 
Masslike HCM 
Masslike HCM displays masslike hypertrophy due to 
focal segmental fibrosis and myocardial disarray [12]. 
This has to be differentiated from myocardial based 
tumours, such as a fibroma. In masslike HCM the 
homogenous signal intensities and perfusion 
characteristics of adjacent normal myocardium are 
identical, as opposed to tumours which show 
heterogenous signal intensity and perfusion that differs 
from the rest of the LV myocardium. The enhancement 
pattern following intravenous contrast also differs in the 
tumours. Myocardial tagging using SSFP technique can 
be helpful in distinguishing masslike HCM from a 
tumour [16]. 
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Noncontigous HCM 
MR imaging is useful in providing a diagnosis of 
noncontigous HCM. Noncontigous HCM manifests as 
hypertrophic segments that are separated by areas of 
normal myocardium. It consists of a pattern where there 
are sudden changes of the myocardial thickness next to 
portions of normal myocardium creating a “lumpy-
bumpy” appearance. This variant can be overlooked or 
underestimated at echocardiography. 
 
Reverse-Curve HCM and Sigmoid HCM 
The reverse-curve and the sigmoid HCM, are 
catergorized by septal morphologic subtypes based on 
long-axis views acquired at end diastole on 
echocardiography [17]. The reverse- curve HCM type is 
frequently linked with hypertension, increased LVOT 
pressure, and family history of sudden cardiac death. 
The characteristics of sigmoid HCM is a basal septal 
bulge which is usually isolated producing a sigmoid 
septal shape. Sigmoid HCM has a tendency to occur in 
elderly patients. 
 
Risk Stratification 
Criterias for HCM risk stratification on cardiac MRI 
include LV myocardial thickness, LV dilatation with 
reduced ejection fraction, fibrosis, LVOT obstruction 
and perfusion defect. 
 
New Developments in CMR Imaging 
Newer developments in CMR imaging such as MR 
spectroscopy and myocardial tagging have been 
studied, however their clinical application still remains 
undecided.  
  MR spectroscopy with 31-phosphorus showed 
altered myocardial energy metabolic profile in HCM 
which correlated with LGE severity. Perhexiline, a 
modulator of substrate metabolism was then seen to 
correct diastolic dysfunction, improve cardiac energetic 
impairment and exercise capacity in symptomatic HCM 
patients [18]. 
  Myocardial tagging quantifies parameteres 
such as strain, strain rate and torsion. Studies in HCM 
have shown, strain is reduced in hypertrophied 
myocardial segments and is inversely related to severity 
[19]. 
CONCLUSION 
CMR imaging is a robust imaging modality for 
distinguishing various types of HCM and for 
differentiating from other cardiomyopathies. It is also a 
strongly recommended imaging modality for risk 
stratification in selected HCM patients. 
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